Sutro Biopharma, Inc. (STRO) News

Sutro Biopharma, Inc. (STRO)

Today's Latest Price: $12.86 USD

0.35 (-2.65%)

Updated Oct 30 4:00pm

Add STRO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter STRO News Items

STRO News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest STRO News From Around the Web

Below are the latest news stories about Sutro Biopharma Inc that investors may wish to consider to help them evaluate STRO as an investment opportunity.

Sutro Bio to discuss STRO-002 interim data on in ovarian cancer on Sept. 9

Sutro Biopharma (STRO) will host a conference call on Sept. 9, at 5:30 p.m. EDT to discuss updated data from ongoing Phase I dose escalation study of anti-Folate Receptor alpha (FRα) antibody-drug conjugate ((ADC)), STRO-002, in ovarian and endometrial cancer, with a data cut-off date of Aug. 31, 2020.Additionally, the company...

Seeking Alpha | September 3, 2020

Were Hedge Funds Right About Souring On Sutro Biopharma, Inc. (STRO)?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]

Yahoo | July 1, 2020

Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the presentation of new preclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate, STRO-002, at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020. The data, being presented by Sutro's Chief Scientific Officer, Trevor Hallam, Ph.D., demonstrates STRO-002's immune-modulating properties and potentiation by PD-L1 blockade.

Yahoo | June 22, 2020

Scott+Scott Attorneys at Law LLP Announces Investigation into Sutro Biopharma, Inc. (STRO)

Scott+Scott Attorneys at Law LLP announces investigation into Sutro Biopharma, Inc. (STRO) and encourages shareholders with losses to contact the Firm

Yahoo | June 11, 2020

Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that the company will present new preclinical data for its folate receptor alpha targeting antibody-drug conjugate, STRO-002, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020.

Yahoo | June 9, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO

Pomerantz LLP is investigating claims on behalf of investors of Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. The investigation concerns whether Sutro and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Yahoo | June 8, 2020

Got $1,000? Buy These 4 Cancer Stocks

These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.

Yahoo | June 8, 2020

Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the appointment of Craig Berman, M.D., as Vice President of Clinical Development and the promotion of Regina Cheng to Vice President of Finance and Controller.

Yahoo | May 21, 2020

Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards-- Carlos Paya, MD, PhD, and Lainie Martin, MD

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the appointments of Carlos Paya, M.D., Ph.D., as Chair of the Scientific Advisory Board and Lainie Martin, M.D., as a member of the Clinical Advisory Board.

Yahoo | May 21, 2020

Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF®, to create a broad variety of optimally designed, next-generation protein therapeutics initially for cancer and autoimmune disorders, today announced the closing of its public offering of 12,650,000 shares of its common stock at a public offering price of $7.75 per share, which includes the exercise in full of the underwriters' option to purchase 1,650,000 shares of common stock. The gross proceeds from this offering were approximately $98.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro.

Yahoo | May 14, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6158 seconds.